HCPCS Level II code A9699 denotes a therapeutic radiopharmaceutical classified as “not otherwise classified,” used for administrations of radiopharmaceutical therapy that lack a dedicated HCPCS identifier. This code matters nationally as radiopharmaceutical therapies expand across oncology and specialty care, creating billing complexity and variation in payer policies. The designation signals novel or less common agents that may require case-by-case coverage and coding decisions.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise view of what A9699 represents clinically and administratively, plus coverage and coding context relevant to major national payers. The publication outlines common billing considerations, typical sites of service, and areas where variation or prior authorization often affects access.

This report provides benchmarks and policy context for therapeutic radiopharmaceuticals billed under A9699, notes common modifiers used in practice (where available), and highlights implications for service lines that deliver radiopharmaceutical therapy. Data not available in the input is explicitly noted where applicable.